Drug intelligence / Profile preview

AZ391

Development stage: Unknown
Modality: Small Molecules

Overview

AZ391 is an investigational small molecule identified as an anti-HIV-1 latency chemotherapeutic that promotes the reactivation of latent HIV-1 provirus. It increases intracellular HIV-1 mRNA levels in a dose-dependent manner, comparable to the BET inhibitor JQ1, without additive or synergistic effects when combined. Developed in the context of latency-reversing agent research, it aims to address HIV persistence by inducing viral transcription from latently infected cells, though no clinical trial data or indications are reported.

Targets

GyrA (DNA gyrase subunit A)

Beyond the preview

Go deeper on AZ391.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZ391.

Explore the full profile